19del与L858R的晚期非小细胞肺癌TKI治疗疗效及预后差异的研究进展  

Research advance on difference of efficacy and prognosis of tyrosine kinase inhibitor treatment for advanced non-small cell lung cancer patients with 19del and L858R mutation

作　　者：李妍 徐兴祥 Li Yan;Xu Xingxiang(Graduate School,Dalian Medical University,Dalian 116044,China;Department of Respiratory Medicine,Subei People's Hospital of Jiangsu Province,Yangzhou 225001,China)

机构地区：[1]大连医科大学研究生院,116044 [2]江苏省苏北人民医院呼吸内科,扬州225001

出　　处：《中国医师杂志》2019年第11期1758-1760,F0003,共4页Journal of Chinese Physician

摘　　要：表皮生长因子受体(EGFR)19号外显子缺失突变(19del)和21号外显子的点突变(L858R)是非小细胞肺癌(NSCLC)中最常见的EGFR突变类型。经EGFR酪氨酸激酶抑制剂(TKI)治疗能够给部分晚期NSCLC患者带来更优的生存获益。临床研究表明,这两种突变类型患者在EGFR-TKI治疗中的获益有所差异。然而,大多数患者通常在治疗12个月后出现耐药,其中最常见的耐药机制是T790M突变。为了研究NSCLC患者对TKI的耐药机制,从而开发新的治疗方法和合理的治疗策略,在整个疾病进展和治疗过程中对肿瘤特征信息的进一步研究是必不可少的。探索比较19del和L858R之间与T790M在获得对TKI耐药方面的差异是极具临床意义的。The epidermal growth factor receptor( EGFR) exon 19 deletion( 19 del) and the L858 R point mutation of exon 21 are the most common types of EGFR mutations in non-small cell lung cancer( NSCLC). Treatment with EGFR tyrosine kinase inhibitors( TKI) can provide better survival benefit for some patients with advanced NSCLC. Clinical studies have shown that patients with these two types of mutations have different benefits in EGFR-TKI therapy. However,most patients treated with EGFR-TKI develop resistance after 12 months of treatment,the most common of which is the EGFR gene T790 M mutation. In order to study the mechanism of resistance to TKI in NSCLC patients,and to develop new therapeutic methods and rational treatment strategies,further research on tumor characteristics in the whole disease progression and treatment process is indispensable. Exploring and comparing the differences between 19 del and L858 R and T790 M in obtaining resistance to TKI is of great clinical significance.

关 键 词：癌 非小细胞肺 受体 表皮生长因子 蛋白激酶抑制剂 外显子 ErbB受体 综述 

分 类 号：R73[医药卫生—肿瘤]